Revisiting ACCORD: Should blood pressure targets in people with and without type 2 diabetes be different?

[1]  Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers. , 2021, Clinical diabetes : a publication of the American Diabetes Association.

[2]  Lee-Jen Wei,et al.  Intensive versus standard blood pressure control in type 2 diabetes: a restricted mean survival time analysis of a randomised controlled trial , 2021, BMJ Open.

[3]  Weili Zhang,et al.  Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. , 2021, The New England journal of medicine.

[4]  J. Coresh,et al.  Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018. , 2021, The New England journal of medicine.

[5]  P. Whelton,et al.  Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT , 2018, Journal of the American Heart Association.

[6]  H. Krumholz,et al.  Systolic Blood Pressure Response in SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in Diabetes): A Possible Explanation for Discordant Trial Results , 2017, Journal of the American Heart Association.

[7]  L. Krakoff.  A Tale of 3 Trials: ACCORD, SPRINT, and SPS3. What Happened? , 2016, American journal of hypertension.

[8]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[9]  J. Cutler,et al.  Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial , 2014, Diabetes Care.

[10]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .